Header Contacts

  • Stockton (California St., Suite B): (209) 466-2626
  • Stockton (California St., Suite L): (209) 474-1458
  • Lodi: (209) 366-2616
  • Tracy: (209) 839-9115
  • PET/CT: (209) 292-8542
  • Manteca: (209) 665-4782
  • Modesto: (209) 524-7000

Clinical Trials

Freenome: The Vallania Study: A Case-Control Study for the Development of Multiomics Blood Tests for Cancer Screening

Brief Summary:

This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.

Mirati NSCLC: A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab Plus Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Brief Summary:

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with unresectable, locally advanced, or metastatic non-squamous NSCLC with KRAS G12C mutation and PD-L1 TPS <50% and who are candidates for first-line treatment.

Lilly JZJX – NSCLC: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC

Brief Summary:

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.

Opening soon:

Gilead ASCENT 5- Triple Negative Breast Cancer: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments.

Personalis, ABRCC-Observational Trial: A clinical trial for residual and recurrent disease detection in Triple Negative Breast Cancer patients.

Please see your treating physician for eligibility for any clinical trial we offer or you may contact our research department below.

Pam Magnasco
Clinical Research Nurse Coordinator

For additional questions not relating to eligibility please contact:

Ashley Mussi
Clinical Regulatory Specialist